Critical patient
Conditions
Interventions
Experimental group:Give dexmedetomidine in combination with butorphanol
Control group:Give conventional analgesic sedation treatment
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. GCS score > 8 points; 2. CPOT score >=3 points and RASS score >=2 point; 3. Aged 18 to 75 years old; 4. Signing an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding; 2. Severe, existing substantial liver disease with clinically significant portal hypertension, Child-Pugh C cirrhosis or acute liver failure; 3. Bronchial asthma or COPD, myasthenia gravis patients; 4. Patients with a history of alcohol or drug abuse; 5. Inability to obtain informed consent or authorization; 6. No sedative, analgesic treatment of patients; 7. GCS score <=8 points; 8. Heart rate <50 beats / min (II / III degree atrioventricular block, except for the installation of pacemaker), MAP <55mmHg; 9. Receive 2 or more sedative or analgesic drugs within 10 or 24 hours; 10. Patients who are allergic to dexmedetomidine or butorphanol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RASS score, CPOT score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Severe complication rate (respiratory depression, sputum, gastrointestinal dysfunction (new occurrence: intestinal obstruction / inhibition of bowel movement / constipation), hypotension, bradycardia);ICU total hospitalization expenses, hospitalization time, ICU hospitalization time, mechanical ventilation time, APACHE II score, SOFA score, delirium score; | — |
Countries
China
Contacts
Public ContactTongwen Sun
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed